• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

单相和三相低剂量炔雌醇复方口服避孕药的出血模式。

Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.

作者信息

Hampton R Moss, Zhang Huabin F, Barnowski Christopher, Wan George J

机构信息

Texas Tech University School of Medicine, Odessa, TX 79763, USA.

出版信息

Contraception. 2008 Jun;77(6):415-9. doi: 10.1016/j.contraception.2008.02.007. Epub 2008 Apr 25.

DOI:10.1016/j.contraception.2008.02.007
PMID:18477490
Abstract

BACKGROUND

This retrospective analysis evaluated the association of age and weight with cycle control in women using either of two formulations of low-estrogen-dose oral contraceptives.

STUDY DESIGN

Data for this secondary analysis were derived from a randomized multicenter trial assessing the efficacy and safety of norgestimate (NGM) 180/215/250 mcg/ethinyl estradiol (EE) 25 mcg (n=1506) and norethindrone acetate 1 mg/EE 20 mcg (n=1057). In this retrospective analysis, the incidence of breakthrough bleeding/spotting (BTB/S) was evaluated in women stratified by age (18-24, 25-34 and >34 years) and weight (<or=123, 124-155 and >155 lb).

RESULTS

A lower percentage of women experienced BTB/S with NGM/EE during most cycles, regardless of age or weight, compared with norethindrone acetate/EE. At Cycle 6, the incidences of BTB/S for NGM/EE versus norethindrone acetate/EE were as follows: 18-24 years, 10.9% versus 29.7% (p<.0001); 25-34 years, 10.9% versus 18.6% (p<.001); >34 years, 8.1% versus 19.1% (p<.005); <or=123 lb, 11.0% versus 25.4% (p<.0001); 124-155 lb, 10.0% versus 22.5% (p<.0001); and >155 lb, 10.0% versus 18.3% (p<.01).

CONCLUSION

NGM/EE provided better cycle control as defined by BTB/S compared with norethindrone acetate/EE, regardless of subject age or weight for six cycles.

摘要

背景

这项回顾性分析评估了使用两种低雌激素剂量口服避孕药配方之一的女性的年龄和体重与月经周期控制之间的关联。

研究设计

这项二次分析的数据来自一项随机多中心试验，该试验评估了诺孕酯（NGM）180/215/250微克/炔雌醇（EE）25微克（n = 1506）和醋酸炔诺酮1毫克/EE 20微克（n = 1057）的疗效和安全性。在这项回顾性分析中，对按年龄（18 - 24岁、25 - 34岁和>34岁）和体重（≤123磅、124 - 155磅和>155磅）分层的女性的突破性出血/点滴出血（BTB/S）发生率进行了评估。

结果

与醋酸炔诺酮/EE相比，无论年龄或体重如何，在大多数周期中使用NGM/EE的女性经历BTB/S的比例较低。在第6周期时，NGM/EE与醋酸炔诺酮/EE的BTB/S发生率如下：18 - 24岁，10.9%对29.7%（p <.0001）；25 - 34岁，10.9%对18.6%（p <.001）；>34岁，8.1%对19.1%（p <.005）；≤123磅，11.0%对25.4%（p <.0001）；124 - 155磅，10.0%对22.5%（p <.0001）；>155磅，10.0%对18.3%（p <.01）。

结论

与醋酸炔诺酮/EE相比，无论受试者年龄或体重如何，在六个周期内，NGM/EE在BTB/S定义的月经周期控制方面表现更佳。

相似文献

1
Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.单相和三相低剂量炔雌醇复方口服避孕药的出血模式。
Contraception. 2008 Jun;77(6):415-9. doi: 10.1016/j.contraception.2008.02.007. Epub 2008 Apr 25.
2
Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).一种新的口服避孕药炔诺酮醋酸酯1毫克/炔雌醇20微克（Loestrin 24 Fe）24天方案的疗效与安全性。
Contraception. 2007 Jan;75(1):16-22. doi: 10.1016/j.contraception.2006.08.004. Epub 2006 Sep 20.
3
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.基于雌二醇的口服避孕药的出血模式和周期控制：雌二醇戊酸酯/地诺孕素与炔雌醇/左炔诺孕酮的 7 个周期随机对照试验。
Contraception. 2009 Nov;80(5):436-44. doi: 10.1016/j.contraception.2009.03.018. Epub 2009 May 13.
4
Association between efficacy and body weight or body mass index for two low-dose oral contraceptives.两种低剂量口服避孕药的疗效与体重或体重指数之间的关联。
Contraception. 2009 Jun;79(6):424-7. doi: 10.1016/j.contraception.2008.12.013. Epub 2009 Mar 4.
5
A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.两种含左炔诺孕酮或炔诺酮的三相口服避孕药的临床比较：一项前瞻性、随机、单盲研究。
Contraception. 1993 Jan;47(1):43-54. doi: 10.1016/0010-7824(93)90108-j.
6
Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.三相诺孕酯/35微克炔雌醇与单相醋酸炔诺酮/20微克炔雌醇的临床比较。周期控制、脂质效应及使用者满意度。
Contraception. 1999 Mar;59(3):161-6. doi: 10.1016/s0010-7824(99)00026-8.
7
Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use.低剂量口服避孕药对体重的影响：一项长达13个周期使用的随机研究结果
J Reprod Med. 2007 Nov;52(11):1030-4.
8
Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.屈螺酮 3mg+炔雌醇 20mcg 24/4 复方口服避孕药与去氧孕烯 150mcg+炔雌醇 20mcg 21/7 复方口服避孕药的出血模式比较。
Contraception. 2009 Nov;80(5):445-51. doi: 10.1016/j.contraception.2009.03.013. Epub 2009 May 9.
9
A clinical overview of a new triphasic contraceptive containing gestodene.一种含孕二烯酮的新型三相避孕药的临床概述。
Int J Fertil. 1989 Sep;34 Suppl:40-9.
10
Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.两种复方激素避孕药的定期和不定期出血模式：标准化新建议的应用
Fertil Steril. 2009 Aug;92(2):434-40. doi: 10.1016/j.fertnstert.2008.07.010. Epub 2008 Oct 18.

引用本文的文献

1
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药
Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4.
2
Triphasic versus monophasic oral contraceptives for contraception.三相口服避孕药与单相口服避孕药用于避孕的比较。
Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD003553. doi: 10.1002/14651858.CD003553.pub3.